Browse the evidence

Resistance exercise training in older adults preserves the capacity for myonuclear accretion (satellite cell fusion), indicating that the failure of aged muscle to hypertrophy is not caused by a lack of new nuclei or a myonuclear domain size ceiling.

If you are an older adult struggling to build muscle despite consistent resistance training, do not assume your muscle fibers have run out of capacity to grow. This research confirms that your muscles can still integrate new nuclei (via satellite cells) just as well as a younger person's. The bottleneck is likely not the structural capacity of the fiber, but rather the efficiency of protein synthesis machinery (ribosomes). Focus on high-intensity resistance training to maximize this preserved capacity.

Higher pre-diagnosis physical activity is associated with significantly lower all-cause mortality in postmenopausal women with early-stage breast cancer, but this benefit does not differ based on the number of cardiometabolic risk factors.

If you have had early-stage breast cancer, staying physically active before and after diagnosis is linked to a lower risk of dying from any cause. This benefit appears to apply whether you have metabolic risk factors (like high blood pressure or diabetes) or not. Aim for regular moderate-to-vigorous activity, such as brisk walking or recreational exercise, as measured in MET-hours per week.

Postprandial glycemic responses to identical meals are highly variable between individuals but predictable within individuals based on personal characteristics.

Recognize that your body's response to food is unique. While general guidelines exist, individual glycemic responses vary significantly. This supports the move towards personalized nutrition rather than relying on universal food labels like GI.

Tirzepatide, a GLP-1/GIP dual receptor agonist, significantly reduces HbA1c levels (up to 2.24%) and body weight (up to 11.2 kg) in patients with type 2 diabetes and obesity, outperforming semaglutide, insulin degludec, and insulin glargine in head-to-head trials.

Tirzepatide is a once-weekly injection for Type 2 Diabetes and obesity that significantly lowers blood sugar and promotes weight loss, often more effectively than other common medications like semaglutide or insulin. It works by mimicking hormones that regulate insulin and appetite. Common side effects like nausea are usually manageable by starting with a low dose and eating smaller, low-fat meals. Due to high costs, check for insurance coverage or assistance programs.

GLP-1 receptor agonists (GLP-1RAs) significantly reduce systolic blood pressure, total stroke risk, and cardiovascular mortality in patients with type 2 diabetes or obesity.

If you have Type 2 Diabetes or Obesity and are at risk for heart disease or stroke, GLP-1 medications (like Semaglutide or Liraglutide) are strongly supported by evidence to lower your risk of heart attack, stroke, and cardiovascular death. Discuss these options with your doctor, especially if you have existing cardiovascular conditions.

Multi-receptor incretin drugs significantly reduce systolic and diastolic blood pressure, with Tirzepatide and Mazdutide showing the most substantial reductions, particularly in non-diabetic populations.

If you have high blood pressure along with overweight or obesity, multi-receptor incretin drugs can help lower both systolic and diastolic blood pressure. This effect is often stronger in people without type 2 diabetes. Discuss with your doctor if these medications could help manage your blood pressure as part of your overall treatment plan.

Visceral adipose tissue (VAT) is the primary driver of cardiometabolic complications (hypertension, T2DM, dyslipidemia) through endocrine dysfunction, RAAS activation, and inflammation, rather than total body weight alone.

Stop relying on BMI to assess your health risk. Focus on reducing visceral fat through lifestyle changes, as this specific fat type drives heart disease and diabetes. Use waist-to-height ratio as a better metric than weight alone.

Semaglutide 2.4 mg is cost-effective for patients with BMI ≥ 30 kg/m² (ICER 18,459 EUR) but may not be cost-effective for patients with BMI ≥ 35 kg/m² (ICER 22,657 EUR) compared to the willingness-to-pay threshold of 20,000 EUR.

For patients with BMI ≥ 35 kg/m², semaglutide 2.4 mg may exceed the willingness-to-pay threshold for cost-effectiveness in Portugal, whereas it remains cost-effective for those with BMI ≥ 30 kg/m².

Elevated liver disease activity, measured by MRI-derived iron-corrected T1 (cT1), is independently associated with a higher risk of major cardiovascular events, atrial fibrillation, heart failure, CVD hospitalization, and all-cause mortality.

If you have elevated liver disease activity (measured by MRI cT1), your risk for heart failure, atrial fibrillation, and other cardiovascular events is significantly higher, independent of your liver fat or standard blood tests. This suggests that assessing liver health via advanced imaging may be crucial for cardiovascular risk stratification, even in those without metabolic syndrome.

Diabetes remission, rather than weight loss itself, is the primary driver for reducing the risk of new-onset microvascular complications.

While weight loss is important, achieving diabetes remission (normal blood sugar without medication) is what actually protects against microvascular complications like kidney and eye damage. Weight loss without remission may not provide this specific protection.

Dulaglutide 1.5 mg reduces systolic blood pressure (SBP) and pulse pressure in patients with type 2 diabetes, with the majority of this reduction (64% for SBP, 86% for pulse pressure) being independent of weight loss.

If you have Type 2 Diabetes, taking dulaglutide (1.5 mg weekly) can lower your systolic blood pressure by about 2.6 mmHg after 6 months. Crucially, most of this benefit comes from the drug's direct effect on your blood vessels and nervous system, not just from losing weight. This means you may see blood pressure improvements even if your weight remains stable.

Higher doses of dulaglutide (4.5 mg) provide additional blood pressure reduction compared to 1.5 mg, but this additional benefit is primarily driven by greater weight loss rather than enhanced weight-independent mechanisms.

Increasing your dulaglutide dose from 1.5 mg to 4.5 mg may lower your blood pressure a bit more, but this extra benefit comes mostly from losing more weight, not from a stronger direct effect on your blood vessels. If you are not losing enough weight on 1.5 mg, the higher dose might help your BP by helping you lose more weight.

Obesity significantly increases the risk of cardiovascular disease, heart failure, and cerebrovascular disease, even in individuals classified as 'metabolically healthy'.

If you have obesity, your risk for heart disease and heart failure is significantly higher than someone with a normal weight, even if your blood pressure and cholesterol are currently normal. You should prioritize cardiovascular health monitoring and weight management strategies to mitigate this elevated risk.

Tirzepatide improves hepatic steatosis and renal outcomes in patients with type 2 diabetes, independent of or additive to weight loss.

Tirzepatide not only helps with blood sugar and weight but also significantly reduces liver fat and protects kidney function in people with type 2 diabetes. This makes it a valuable option for those at risk of liver or kidney complications.

Women with obesity exhibit distinct physiological and psychological responses to weight management compared to men, including greater neural sensitivity to food rewards, higher baseline leptin levels, and a tendency toward peripheral (gluteo-femoral) fat distribution which offers metabolic protection until menopause.

If you are a woman with obesity, your body may respond differently to food and stress than a man's due to hormonal and neural factors. This is not a failure of willpower. Post-menopause, your fat distribution may shift to the abdomen, increasing health risks. Work with providers who assess your specific hormonal status and mental relationship with food, rather than just applying a generic 'calories in, calories out' model.

Post-menopausal women face a significantly increased risk of cardiovascular disease and metabolic complications due to the shift from protective gluteo-femoral fat to visceral, perivascular, and epicardial fat accumulation following estrogen decline.

After menopause, your body stores fat differently, often around organs (visceral/epicardial fat), which increases heart disease risk even if your BMI stays the same. Focus on maintaining muscle mass and reducing visceral fat through exercise and diet, as standard BMI checks may not capture this new risk.

In strength-trained individuals, resistance training frequency (1x vs 3x per week) produces equivalent maximal strength (1RM) and muscle hypertrophy (CSA) gains when total training volume is equalized.

If you are an experienced lifter, you do not need to train a muscle group three times a week to get bigger or stronger. You can train it once a week, provided you perform the same total amount of work (volume) and intensity. Focus on getting your sets in during that single session rather than spreading them out for frequency's sake.

Long-term intentional weight loss via intensive lifestyle intervention causes greater bone mineral density loss at the hip in men with type 2 diabetes compared to control, increasing frailty fracture risk.

If you have type 2 diabetes and are planning to lose weight, be aware that men may experience greater bone loss at the hip over the long term. To mitigate this, ensure your weight loss plan includes bone-preserving strategies such as resistance training, adequate calcium and vitamin D intake, and regular monitoring of bone density, rather than relying solely on caloric restriction and walking.

Training to muscular failure elongates recovery time courses and increases fatigue perception compared to non-failure training, potentially impairing subsequent performance if insufficient recovery time is allowed between sessions.

Avoid training to failure on exercises scheduled before high-priority sessions (like heavy singles or technical lifts). Reserve failure training for isolation movements, the last set of a session, or when you have ample recovery time (48+ hours) before training the same muscle group again. This preserves performance for important lifts.

Exercise selection significantly impacts recovery time, with lower body, multi-joint, eccentric-heavy, and lengthened-position exercises requiring longer recovery periods (48-72 hours) compared to upper body or isolation movements.

Schedule lower body, multi-joint, or eccentric-heavy exercises (like squats, deadlifts, or lengthened partials) with at least 48 hours of rest before training the same muscle groups again. Use upper body or isolation exercises for more frequent training sessions.

Home-based training (HBT) is an effective alternative to supervised exercise training when SET is not feasible, provided it is monitored.

If you can't go to a supervised clinic, do home-based walking exercises. Start with 20 minutes and build up to 60 minutes, 3 times a week. Use a pedometer, smartwatch, or logbook to track your activity. This is a valid alternative to supervised training.

High-intensity interval training (HIIT) engages a unique subset of skeletal muscle signaling networks compared to work-matched moderate-intensity continuous training (MICT), specifically involving kinases and pathways associated with plasma lactate levels.

If you are healthy and untrained, HIIT can trigger unique muscle signaling pathways linked to metabolic health (like lactate response) that moderate continuous training does not, even when the total work done is the same. This suggests HIIT is a potent tool for metabolic adaptation.

High-intensity interval training (HIIT) elicits higher plasma lactate concentrations than work-matched moderate-intensity continuous training (MICT) during the exercise bout.

If you do HIIT, you will produce more lactate than if you did moderate continuous training of the same work. This is expected and part of what drives the unique adaptations.

Tirzepatide (5, 10, and 15 mg once weekly) achieves glycaemic targets (HbA1c < 7.0% and ≤ 6.5%) significantly faster than semaglutide 1 mg and insulin degludec in patients with type 2 diabetes.

If you have type 2 diabetes, starting tirzepatide will likely lower your blood sugar (HbA1c) to target levels faster than starting semaglutide 1 mg or insulin degludec, even though you start on a low dose. You will need to wait 4-20 weeks to reach your full maintenance dose depending on the strength chosen, but clinical targets are met sooner with tirzepatide than with the comparators.